pyrimethamine has been researched along with Muscular Weakness in 2 studies
Maloprim: contains above 2 cpds
| Excerpt | Relevance | Reference |
|---|---|---|
| " Participants were actively monitored for adverse events for the first 14 days after each treatment, and then passively followed until their next study medication treatment, or withdrawal from study." | 2.73 | Safety and tolerability of combination antimalarial therapies for uncomplicated falciparum malaria in Ugandan children. ( Clark, TD; Dorsey, G; Jagannathan, P; Kamya, MR; Maiteki-Sebuguzi, C; Njama-Meya, D; Nzarubara, B; Rosenthal, PJ; Staedke, SG; Talisuna, AO; Yau, VM, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Marzolini, MAV | 1 |
| Jaunmuktane, Z | 1 |
| Roddie, C | 1 |
| O'Reilly, M | 1 |
| Chiodini, P | 1 |
| Peggs, KS | 1 |
| Maiteki-Sebuguzi, C | 1 |
| Jagannathan, P | 1 |
| Yau, VM | 1 |
| Clark, TD | 1 |
| Njama-Meya, D | 1 |
| Nzarubara, B | 1 |
| Talisuna, AO | 1 |
| Kamya, MR | 1 |
| Rosenthal, PJ | 1 |
| Dorsey, G | 1 |
| Staedke, SG | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Longitudinal Comparison of Combination Antimalarial Therapies in Ugandan Children: Evaluation of Safety, Tolerability, and Efficacy[NCT00123552] | Phase 3 | 601 participants (Actual) | Interventional | 2004-11-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for pyrimethamine and Muscular Weakness
| Article | Year |
|---|---|
Safety and tolerability of combination antimalarial therapies for uncomplicated falciparum malaria in Ugandan children.
Topics: Amodiaquine; Anorexia; Antimalarials; Artemether, Lumefantrine Drug Combination; Artemisinins; Artes | 2008 |
1 other study available for pyrimethamine and Muscular Weakness
| Article | Year |
|---|---|
Toxoplasmosis initially presenting as neurological sequelae of chimeric antigen receptor T-cell therapy.
Topics: Cognitive Dysfunction; Humans; Immunotherapy, Adoptive; Leukemia, Lymphocytic, Chronic, B-Cell; Male | 2019 |